Cell-based therapy for cancer is a promising new field. Among cell types that can be used for this purpose, mesenchymal stem cells (MSCs) appear to hold great advantage for reasons including easier propagation in culture, possible genetic modification to express therapeutic proteins and preferential homing to sites of cancer growth upon in vivo transfer. The present study evaluated the potential of genetically modified MSC, constitutively expressing interferon ( 
Introduction
Prostate cancer is the most commonly diagnosed cancer in adult males in the Western world and the second leading malignancy next to lung cancer. 1 Improvements in early diagnosis have identified more patients with clinically localized disease. 2 Local therapy such as radical prostatectomy improves the overall survival; however, most deaths from prostate cancer are due to metastases that are resistant to conventional therapies. 3 Therefore, more effective therapies that can not only eradicate localized tumors but also prevent their metastasis are needed. One possible therapeutic molecule for prostate cancer is interferon (IFN)-b, which is a member of the type I IFN family. 4 IFN-b suppresses tumor cell growth by induction of differentiation, S-phase accumulation and apoptosis. [4] [5] [6] [7] High concentrations of IFN-b are known to inhibit malignant cell growth in vitro. 4, 8 However, the therapeutic utility of IFN-b in vivo is limited by its excessive toxicity when administered systemically at high doses. 9, 10 Systemic IFN therapy for most solid tumors also has shown limited response as the short half-life of IFN-b protein could not reach the required concentrations to suppress tumor cell growth, downregulate angiogenesis and enhance host immune effector function. 4, 11 Thus, cell-based therapies are emerging as useful alternatives for IFN therapy for metastatic prostate disease.
Mesenchymal stem cells (MSCs) are attractive celltherapy vehicles for the delivery of agents into tumor cells. Previous studies provide evidence supporting the rationale for genetically modified MSC to deliver therapeutic proteins directly into the tumor microenvironment to produce high concentrations of antitumor proteins directly within the tumor mass, which have been shown to blunt tumor growth kinetics in experimental animal models. [12] [13] [14] [15] [16] The present study describes the potential of genetically modified MSC, constitutively expressing IFN-b in reducing tumor growth in a therapy model of prostate cancer lung metastasis. Targeted homing of MSC producing IFN-b, at tumor sites in the lungs, was found to mediate antitumor effects by multiple mechanisms including induction of tumor apoptosis, antiangiogenesis and by increasing natural killer (NK) cell activity. These results demonstrate the potential of cell-based IFN-b therapy for prostate cancer lung metastasis.
Results

High-level expression and bioactivity of IFN-b produced by rAAV
The open reading frame of murine IFN-b was subcloned in a recombinant adeno-associated virus (rAAV) vector under the cytomegalovirus/chicken b-actin promoter (Figure 1a) . High-level expression of the transgenic protein was confirmed by western blot analysis. In all, 293 cells were mock-transduced or transduced with rAAV encoding IFN-b. Forty-eight hours later, supernatants from transduced cells were analyzed by western blot using an antibody for IFN-b. Results shown in Figure 1b indicating two bands of IFN-b with molecular weights 18 and 21 kDa confirmed the presence of unglycosylated and glycosylated forms of the transgenic protein.
To determine the transduction efficiency of rAAV-IFNb in mouse MSC, the cells were either mock-transduced or transduced with rAAV6-IFN-b at 1000 MOI (multiplicity of infection). One week later, the cells were harvested, fixed on slides and immunohistochemistry was performed using a mouse IFN-b antibody. Result indicating efficient transduction of mouse MSC by rAAV-IFN-b and expression of the transgenic protein is shown in Figure 1c . IFN-b concentration was determined by enzyme-linked immunosorbent assay (ELISA) and found to be 120 pg ml À1 , which amounts to approximately 8 Â 10 À4 pg per cell. To determine the bioactivity of rAAV-produced IFN-b, an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was performed using TRAMP-C2 cells in vitro. Results of the proliferation assay indicated inhibition of TRAMP-C2 cell growth by 44% (Po0.004), following the addition of supernatant from rAAV6-IFN-b-transduced MSC containing approximately 4 ng of the vector-produced cytokine. The inhibition observed was comparable to that using recombinant IFN-b protein (Figure 2 ).
Systemic application of MSC-AAV-IFN-b reduced the growth of TRAMP-C2 prostate cancer cells in the lung
Cohorts of C57BL/6 mice were injected with 5 Â 10 5 TRAMP-C2 cells through tail vain. Ten days later, mice were given no treatment or MSCs (2 Â 10 5 ) that were transduced with rAAV-IFN-b or rAAV-green fluorescent protein (GFP). Cohorts of mice from each group were killed on day 30 to determine the effect of therapy, and the remaining mice were killed after 75 days. The number and size of tumor nodules in the lungs of untreated mice and that given MSC transduced with rAAV-GFP were significantly higher than those in mice treated with MSC transduced with rAAV-IFN-b (Po0.0056 and Po0.0035 compared to untreated and rAAV-GFP-treated groups respectively; Figure 3a ). Cell and gene therapy for prostate cancer lung metastasis C Ren et al analysis of lung section provided evidence for homing of MSC to the tumor site in the lungs as shown in Figure 5 . Expression of IFN-b in MSC that homed to lungs was also confirmed by staining with an IFN-b primary antibody, followed by incubation with Alexa-Fluor-488-conjugated secondary antibody (green).
IFN-b-expressing MSC therapy was found to increase NK cell activity
As the present study was performed in immunocompetent mice, and based on the role of IFN-b in activating immune effectors, we determined the number of CD8+ T cells and NK cells, 20 days after initiation of the therapy. Cell and gene therapy for prostate cancer lung metastasis C Ren et al Mononuclear cells from the lung and the spleen were isolated and stained with anti-CD8 and anti-NK1.1 antibodies and analyzed by flow cytometry. About 12% of lung mononuclear cells were NK cells in MSC-IFN-btreated mice, whereas in untreated and AAV-GFP-treated mice, there was 4% of NK cells in the lung. There was no significant difference in CD8+ T-cell population between the groups. Mice that were treated with MSC-IFN-b plasmid exhibited only a slight increase in NK cells in the lung, which was not statistically significant ( Figure 6 ).
Discussion
The utility of many biological agents as recombinant proteins for the treatment of metastatic prostate disease is often limited by their short half-life or excessive toxicity. Therefore, more effective therapies that can provide sustained antitumor effects on metastatic tumors can increase patient survival. Studies have shown that MSC, engrafted in tumors, could potentially serve as delivery vehicles of anticancer agents to malignant cells. 13, 16 The rationale for using bone marrow-derived stem cells for delivering therapies to tumors is based on the concept that bone marrow is a source of circulating stem cells that are recruited from the blood into peripheral solid organs in times of tissue stress or injury. [17] [18] [19] [20] Because the microenvironment of solid tumor is similar to the environment of injured tissue, 21, 22 it is believed that solid tumors may provide a permissive environment for the engraftment of exogenously given MSC. 13 Thus, the tumor-homing property of MSC provides an attractive opportunity for targeted delivery of transgenes into the sites of tumor growth.
Mesenchymal stem cells are attractive as a cellular vehicle for the expression of therapeutic proteins by gene transfer because of several advantages such as their ease in harvesting, isolation and expansion, transduciblity with viral vectors, systemic or local delivery and refractory to host immune responses. 23, 24 Recent studies have reported successful engraftment of ex vivo-transduced MSC at the site of lung metastasis of breast cancer, gliomas, colorectal tumors and ovarian tumors in animal models. [25] [26] [27] [28] MSCs are capable of long-term transgene expression. 29 Genetic modification of MSC has been used to overcome the problem of limited viability and engraftment of the transplanted cells. Indeed, genetic modification can improve survival, metabolic characteristics, proliferative capacity or differentiation of MSC. In addition, MSCs can be engineered to serve as vehicles for gene therapy, in which secreted proteins can exert paracrine or endocrine actions that may augment therapeutic benefits. A recent study has shown that MSC of various origins can also stimulate the growth of tumor cells. 30 Hence, it is important to obtain high-efficiency-transduction MSC and expression of transgenic protein with antitumor property for therapeutic application. We have recently demonstrated high-efficiency transduction of MSC by rAAV. 31 Interferon-b is a potent antiangiogenic and antimetastatic molecule. It not only inhibits growth and migration of endothelial cells, but also downregulates expression of molecules for angiogenesis and invasion. 32, 33 Prostate cancer cells and several other types of tumor cells are more sensitive to IFN-b than IFN-a. [34] [35] [36] Studies have shown that in vitro modified MSC can deliver IFN-b into the tumor microenvironment, and IFN-b exerts local paracrine effect after it is delivered into tumors.
The present study demonstrates that intravenous injection of MSC, genetically modified to produce IFN-b using an rAAV, into mice with established TRAMP-C2 pulmonary metastases suppressed the tumor growth. Despite the antitumor effects observed, there was an absence of higher systemic levels of the transgenic protein, suggesting the local effects of MSC-produced IFN-b in the tumor microenvironment. This, in fact, is advantageous because it may reduce undesired side effects such as cell toxicity encountered in IFN-b protein therapy. A combination of mechanisms including tumor apoptosis, antiangiogenesis and induction of NK cell activity was found to affect the antitumor activity of this pleiotrophic cytokine. IFN-b is known to cause antiangiogenic effect by blocking endothelial cell migration and downregulation of FGF (fibroblast growth factor) gene expression. 33, 37 The antitumor effects of IFNs through immune stimulation are known to be mediated by induction of major histocompatibility complex class 1 expression, increasing the activity of cytolytic T cells, macrophages and NK cells. 36, 37 Although there was a significant increase in the NK cell population in the lungs of mice treated with MSC-producing IFN-b, there was no significant difference in the CD8+ T-cell population. This data, while implying the role of innate effectors, cannot completely rule out the possible role of adaptive immune Cell and gene therapy for prostate cancer lung metastasis C Ren et al response through cytotoxic T lymphocytes. It remains possible that the ratio of tumor-specific cytotoxic T lymphocytes to total CD8+ cells measured was not relatively substantial. The indirect effect of IFN-b by upregulating immune effectors will also be advantageous in situations in which metastatic tumor cells develop resistance to antiproliferative effects of the cytokine. Engraftment of intravenously administered MSC in any of the healthy organs, including heart, liver, spleen, kidney, brain and muscle, was not observed in the present study. This finding is consistent with the earlier reports that systemically administered MSCs engraft poorly in healthy tissues. 38 This property adds advantage toward using MSC to express IFN-b and avoid organ toxicity. Thus, preferential homing of MSC to tumor sites and the potential of genetically modified MSC therapy for antitumor effects could also be translated for treating other primary and metastatic tumors. Before clinical translation of this strategy, more studies need to be done to determine the longevity of genetically modified MSC and its long-term effects in vivo.
Materials and methods
Cell lines and reagents
The human embryonal kidney cell line HEK293 and the mouse metastatic prostate cancer cell line TRAMP-C2 were purchased from the American Type Culture Collection (Manassas, VA, USA). The 293 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum, penicillin (100 U ml À1 ) and streptomycin (100 mg ml À1 ) (Cellgro, Herndon, VA, USA) and the TRAMP-C2 cells were maintained in Dulbecco's modified Eagle's medium with 4.5 g l À1 glucose (Media Inc., Herndon, VA, USA), 5% fetal bovine serum, 5% Nu-serum IV (Becton, Bedford, MA, USA), 10 À8 mol l À1 dihydrotestosterone (Sigma-Aldrich, St Louis, MO, USA), insulin (Sigma-Aldrich) and 25 mg ml À1 penicillin/streptomycin (Cellgro) at 37 1C in a CO 2 atmosphere. Restriction endonucleases and other modifying enzymes were purchased from either New England Biolabs (Beverly, MA, USA) or Promega Corporation (Madison, WI, USA). Anti-PARP-p85 antibody was purchased from Promega, the Ki67 antibody from Abcam (Cambridge, MA, USA), Factor VIII antibody from Ventana (Tucson, AZ, USA) and the IFN-b antibody from United States Biological (Swampscott, MA, USA).
Vector construction, packaging and purification
The open reading frame of mouse IFN-b was amplified by PCR from the plasmid pmGb-3.1 (kind gift from Dr Taniguchi, Cancer Institute, Japanese Foundation for Cancer Research, Japan) and cloned in a recombinant AAV plasmid pAAV-CA containing the cytomegalovirus/chicken b-actin promoter. Nucleotide sequence of the cloned fragment was verified by automated sequencing. Packaging of rAAV-IFN-b was performed by transient transfection in 293 cells with the helper plasmid pDP6 as described. 39 Purification of rAAV was done by iodixanol density-gradient and heparin affinity chromatography as described. 40 Particle titers of the rAAV were determined by quantitative slot blot and real-time PCR. 41 Western blot rAAV-IFN-b was transduced to 293 cells at an MOI of 1000. After 48 h, mock-transduced and vector-transduced cells were lysed using lysis buffer (10 mM Tris-Cl (pH 7.4), 0.15 M NaCl, 5 mM EDTA and 1% Triton X-100) containing 100 mg ml À1 of protease cocktail inhibitor (Sigma-Aldrich). Protein content of the lysates was determined using Bio-Rad Dc protein assay kit. Ten micrograms of protein from each sample were separated in 10% SDS-polyacrylamide gel electrophoresis, subsequently transblotted onto polyvinylidene fluoride membrane. The membranes were blocked in blocking buffer (5% powdered nonfat milk in phosphate-buffered saline (PBS) containing 0.05% Tween 20). The blot was probed with a monoclonal, rat anti-mouse IFN-b antibody followed by binding with an anti-rat secondary antibody (Molecular Probes, Eugene, OR, USA). IFN-b protein band was detected with an enhanced chemiluminescence kit (ECL; Amersham Biosciences/GE Healthcare, Little Chalfont, UK).
Isolation and culturing of mouse MSC
C57BL/6 mice were purchased from the National Cancer Institute-Frederick Cancer Research Facility (Frederick, MD, USA). All animal protocols were performed following the guidelines of the Institutional Animal Care and Use Committee. To obtain bone marrow stromal cells, 6-to 8-week-old male mice were killed, bone marrow was flushed from the femur and tibia, and the marrow mononuclear cells were purified by ficoll gradient. Bone marrow stromal cells were grown in aminimum essential medium containing 10% fetal bovine serum and supplemented with 10 À9 M fibroblast growth factor-2 to maintain cells in pluripotent and undifferentiated state. 42, 43 Periodically, floating cells were removed and fresh medium replenished. Residual macrophages from the MSC culture were removed by IMAC using anti-mouse CD11b beads (BD Biosciences, San Diego, CA, USA). After 14 days, the adherent stromal cells were split before attaining confluence to avoid possible onset of differentiation. The cells were routinely prepared and used for in vitro and in vivo studies as low-passage cultures (passages 4-8). Undifferentiated MSCs were transduced with 1000 MOI of rAAV6-IFN-b or rAAV6-GFP. Before transduction, cells were removed off the growth medium and washed once with serum-free Opti-MEM (Gibco-BRL, Gaithersburg, MD, USA). Virus infection was performed in 125 ml of Opti-MEM for 2 h at 37 1C after which complete medium with fibroblast growth factor-2 was added. One week later, cells were harvested by tryspinization and resuspended in PBS for injection. In situ staining of IFN-b in cultured MSC following transduction was performed using a rat anti-mouse IFN-b antibody.
MTT assay
TRAMP-C2 cells were seeded in 96-well plates (Falcon 3072; Becton-Dickinson, Lincoln Park, NJ, USA) at 7.5 Â 10 3 cells per well and incubated at 37 1C for 24 h. Supernatants from mock-transduced and rAAV6-IFN-btransduced MSC were added to the plate and returned to the incubator for 3 days. MTT dye was added to each well for the last 4 h of treatment. The reaction was stopped by the addition of dimethyl sulfoxide, and the Cell and gene therapy for prostate cancer lung metastasis C Ren et al optical density was determined at 570 nm on a multiwell plate reader (Model 3550; Bio-Rad, Mississauga, Canada). Background absorbance of the medium in the absence of cells was subtracted. All samples were assayed in triplicate, and the mean for each experiment was calculated. Results were expressed as a percentage of control, which was considered as 100%.
In vivo studies
Eight-week-old male C57BL/6 mice were purchased from the National Cancer Institute-Frederick Cancer Research Facility. Handling of the animals was done in accordance with the guidelines of the Institutional Animal Care and Use Committee. For establishing lung metastasis, 5 Â 10 5 TRAMP-C2 cells were injected by tail vein into each mouse. Ten days later, when tumors were established in the lungs, 5 Â 10 5 MSCs that were unmodified or transduced with rAAV6-IFN-b or rAAV6-GFP were given by i.v. injection through the tail vein in a volume of 200 ml. The MSC injection was given two times.
Immunohistochemistry
Cohorts of mice were killed at two different time points (30 days and 75 days after the injection of MSC) and tissues were harvested and 5-mm thick paraffin sections were made. Tissue sections were dewaxed in xylene and then rehydrated in graded alcohol. Endogenous peroxidase activity was blocked with 0.3% (v/v) hydrogen peroxide in methanol before washing the slides in water. Slides were incubated in citrate buffer (pH 6.0) for 20 min in a steamer for antigen retrieval for Ki67, anti-PARP-p85 and IFN-b. For Factor VIII-related antigen, pepsin antigen retrieval was used by incubating slides in 0.5 mg ml À1 pepsin A in pH 2.0 HCl (0.01 N) for 15 min at 37 1C. Nonspecific binding was blocked by incubation in 5% (v/v) normal serum (depending on the animal in which the secondary antibody was raised). The primary antibodies were used in the following dilutions: Ki67, 1:50; anti-PARP p85 fragment, 1:100; Factor VIII-related antigen, 1:40 and IFN-b, 1:500. Following binding with primary antibodies, slides were incubated with respective secondary antibodies conjugated to horseradish peroxidase. The bound antibody was visualized using the peroxidase-based Vectastain Elite ABC Kit (Vector Laboratories Ltd, Peterborough, UK). The substrate reaction was stopped by washing the slides in running water. Finally, the slides were lightly counterstained in hematoxylin.
Serum ELISA
Blood was collected from mice at different time points and sera were stored frozen in À80 1C until use. To quantitate the amount of IFN-b protein, sera were used in triplicates in an ELISA, specific for mouse IFN-b (PBL Biomedical Laboratories, Piscataway, NJ, USA) in accordance with the manufacturer's protocol and analyzed at an absorbance of 450 nm. The minimum sensitivity of detection was 15.6 pg ml
À1
.
Determination of MSC homing to lung
MSC homing to tumor tissue in the lung in vivo was determined by labeling with the fluorescent dye CM-DiI (Molecular Probes) before in vivo administration. The dye was reconstituted at a concentration of 1 mg ml À1 in dimethyl sulfoxide. Cultured MSCs were trypsinized, washed with PBS and resuspended at a concentration of 10 6 cells in 1 ml Dulbecco's PBS containing 2 mg CM-DiI dye. Cells were labeled by incubation at 37 1C for 5 min followed by 15 min at 4 1C in the dark. Unincorporated dye was then removed by centrifugation at 300 g for 5 min followed by two washes in PBS. Cells were resuspended in PBS and injected by tail vein to mice bearing TRAMP-C2 tumors in the lung. Two weeks later, mice were killed and 5-mm thick paraffin sections were made of lungs. Visualization of labeled MSC was based on fluorescence of CM-DiI dye (red), and the expression of IFN-b was determined by using a fluorescent secondary antibody (green) following incubation with the IFN-b primary antibody. The stained slides were analyzed in a Leica DM 2RB fluorescence microscope.
Analysis of immune effectors
Spleens and lungs from mice from different groups were disrupted using wire mesh screens, and erythrocytes were lysed by treatment with lysis buffer (8.29 g NH 4 Cl, 1.0 g KHCO 3 and 0.037 g EDTA per l). MNCs were centrifuged at 1500 r.p.m. for 5 min. The cells were washed in PBS containing 2% (w/v) BSA and 0.2% (w/v) NaN 3 and stained with fluorescein isothiocyanateconjugated anti-NK1.1 and anti-CD8 APC antibodies (BD PharMingen, San Diego, CA, USA). The stained cells were subjected to fluorescence-activated cell sorter analysis to enumerate the percentage of positive cells.
